Assessing residual cancer burden in breast cancer patients undergoing neoadjuvant chemotherapy using the OptiScan probe and machine learning

Shadi Momtahen; Maryam Momtahen; Ramani Ramaseshan; Farid Golnaraghi

doi:10.1117/12.3009823

12 March 2024 Assessing residual cancer burden in breast cancer patients undergoing neoadjuvant chemotherapy using the OptiScan probe and machine learning

Shadi Momtahen, Maryam Momtahen, Ramani Ramaseshan, Farid Golnaraghi

Author Affiliations +

Proceedings Volume 12838, Biophotonics in Exercise Science, Sports Medicine, Health Monitoring Technologies, and Wearables V; 1283803 (2024) https://doi.org/10.1117/12.3009823
Event: SPIE BiOS, 2024, San Francisco, California, United States

Abstract

Breast cancer patients undergoing neoadjuvant chemotherapy (NAC) require precise and accurate evaluation of treatment response. Residual cancer burden (RCB) estimation is a critical prognostic tool used in breast cancer outcomes assessment. In this pioneering study, we introduce the OptiScan probe, an innovative machine-learning-based optical biosensor, to assess residual cancer burden in patients undergoing NAC. The study enrolled 32 patients (mean age: 61.8 years), with comprehensive data collected pre- and post-each NAC cycle. Using the Modified Diffusion Equation (MDE) algorithm and advanced regression analysis, we meticulously calculated the optical properties and generated functional images of both healthy and affected breast tissues. Leveraging these insights, a robust machine learning model was developed, harnessing optical parameter values and breast cancer imaging features to predict RCB values. The predictive model showcased exceptional performance, achieving an impressive accuracy of 96.875% and 96.88% sensitivity in predicting RCB based on optical property alterations. These findings underscore the potency of the OptiScan probe as a pivotal tool for assessing breast cancer response post-NAC. This innovative approach holds promise as a noninvasive and accurate method for monitoring patient responses, contributing to improved treatment decisions and patient outcomes. By combining the power of machine learning with cutting-edge optical imaging, this study marks a significant stride toward personalized and effective breast cancer management.

Conference Presentation

(2024) Published by SPIE. Downloading of the abstract is permitted for personal use only.

Citation Download Citation

Shadi Momtahen, Maryam Momtahen, Ramani Ramaseshan, and Farid Golnaraghi "Assessing residual cancer burden in breast cancer patients undergoing neoadjuvant chemotherapy using the OptiScan probe and machine learning", Proc. SPIE 12838, Biophotonics in Exercise Science, Sports Medicine, Health Monitoring Technologies, and Wearables V, 1283803 (12 March 2024); https://doi.org/10.1117/12.3009823

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available